Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group-Reference-Cited by-同舟云学术

Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group

Published:2019-05 Issue:5 Volume:25 Page:932-940
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Patriarca Francesca,Masciulli Arianna,Bacigalupo Andrea,Bregante Stefania,Pavoni Chiara,Finazzi Maria Chiara,Bosi Alberto,Russo Domenico,Narni Franco,Messina Giuseppe,Alessandrino Emilio Paolo,Carella Angelo Michele,Milone Giuseppe,Bruno Benedetto,Mammoliti Sonia,Bruno Barbara,Fanin Renato,Bonifazi Francesca^ORCID,Rambaldi Alessandro

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference46 articles.

1. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

2. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status;Gangat;J Clin Oncol,2011

3. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment);Passamonti;Blood,2010

4. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN International Working Group;Kröger;Leukemia,2015

5. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelofibrosis and allogeneic transplantation: critical points and challenges;Frontiers in Oncology;2024-06-20

2. Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis;Laboratory Medicine;2024-04-11

3. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-03-15

4. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management;American Journal of Hematology;2024-03-07

5. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis;Pathology;2024-02